Broad neutralization against SARS-CoV-2 variants induced by ancestral and B.1.351 AS03-Adjuvanted recombinant Plant-Derived Virus-Like particle vaccines

Dubé, Charlotte; Paris-Robidas, Sarah; Andreani, Guadalupe; Gutzeit, Cindy; D’Aoust, Marc‐André; Ward, Brian J.; Trépanier, Sonia

doi:10.1016/j.vaccine.2022.05.046

Cited by 9 publications

(8 citation statements)

References 90 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Enveloped VLPs with a modified viral spike protein were produced using transient expression in N. benthamiana , resulting in VLPs similar in size and shape to the SARS-CoV-2 virus displaying a high density of spike proteins on their surface. After successful phase II and III clinical trials, this vaccine was approved by Canadian Health Authorities in early 2022 ( Dubé et al., 2022 ).…”

Section: Discussionmentioning

confidence: 99%

Plant production of a virus-like particle-based vaccine candidate against porcine reproductive and respiratory syndrome

et al. 2023

View full text Add to dashboard Cite

Porcine reproductive and respiratory syndrome (PRRS) is a disease leading to spontaneous abortions and stillbirths in sows and lowered life quality and expectancy in growing pigs. PRRS is prevalent worldwide and has significant economic impacts to swine industries around the globe. Co-expression of the two most abundant proteins in the viral envelope, the matrix protein (M) and glycosylated protein 5 (GP5), can produce a neutralizing immune response for the virus providing a potentially effective subunit vaccine against the disease, but these proteins are difficult to express. The goal of this research was to display antigenic portions of the M and GP5 proteins on the surface of tobacco mosaic virus-like particles. A modified tobacco mosaic virus coat protein (TMVc) was transiently expressed in Nicotiana benthamiana leaves and targeted to three subcellular compartments along the secretory pathway to introduce glycosylation patterns important for M-GP5 epitope immunogenicity. We found that accumulation levels in the apoplast were similar to the ER and the vacuole. Because glycans present on plant apoplastic proteins are closest to those present on PRRSV proteins, a TMVc-M-GP5 fusion construct was targeted to the apoplast and accumulated at over 0.5 mg/g of plant fresh weight. TMVc virus-like particles self-assembled in plant cells and surface-displayed the M-GP5 epitope, as visualized by transmission electron microscopy and immunogold localization. These promising findings lay the foundation for immunogenicity and protective-immunity studies in animals to examine the efficacy of this vaccine candidate as a measure to control PRRS.

show abstract

Section: Discussionmentioning

confidence: 99%

Plant production of a virus-like particle-based vaccine candidate against porcine reproductive and respiratory syndrome

et al. 2023

View full text Add to dashboard Cite

show abstract

“…The function of CoVLP was evaluated using homologous and heterologous prime-boost regimen in mice. As revealed by the result, CoVLP is capable of inducing strong and extensive cross-reaction neutralizing antibody (NAb) reaction against several variant virus strains of COVID-19 [142] . During the phase Ⅰ trial of CoVLP, the serum NAb titers were up-regulated significantly, which were ten-fold higher than titers of COVID-19 convalescent.…”

Section: The Current Research Status Of the Covid-19 Vaccinesmentioning

confidence: 99%

From Immunogen to COVID-19 vaccines: Prospects for the post-pandemic era

Miao¹,

Chen²,

Cao³

et al. 2023

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

“…The CoVLP vaccine consists of stabilized pre-fusion S protein self-assembled VLPs formulated with Adjuvant System 03（ASO3）and Nonmethylated cytosine phosphate guanine dinucleotide sequence (CpG) as adjuvants. Results of clinical phase I trials have shown that IL-4 and IFN-γ immune responses are well elicited in individuals [88] , [89] . CoVLP is currently in phase III clinical trial (NCT04636697) enrolling 30,918 participants in North America and has shown favorable efficacy and safety profiles for CoVLP [90] , [91] .…”

Section: Current Status Of Research On Vlps Vaccines Against Covid-19mentioning

confidence: 99%

A perspective on SARS-CoV-2 virus-like particles vaccines

Gao

Xia

Liu

et al. 2023

International Immunopharmacology

View full text Add to dashboard Cite

Broad neutralization against SARS-CoV-2 variants induced by ancestral and B.1.351 AS03-Adjuvanted recombinant Plant-Derived Virus-Like particle vaccines

Cited by 9 publications

References 90 publications

Plant production of a virus-like particle-based vaccine candidate against porcine reproductive and respiratory syndrome

Plant production of a virus-like particle-based vaccine candidate against porcine reproductive and respiratory syndrome

From Immunogen to COVID-19 vaccines: Prospects for the post-pandemic era

A perspective on SARS-CoV-2 virus-like particles vaccines

Contact Info

Product

Resources

About